Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PANACEA LIFE SCIENCES HOLDINGS, INC.EXDI · Entity 9699 | Director · 10% owner | December 11, 2019 | December 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PANACEA LIFE SCIENCES HOLDINGS, INC.
Report date December 11, 2019 · Filed December 13, 2019
Jointly reported with Ceed2Med LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, Par Value $0.0001 per ShareSEC Table I · non-derivative | Direct | 6,435,691 |
Reported balance
After 2019-12-11 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2019-12-11 · Other · Disposed 1,200,000 · Balance 6,435,691 F1: Represents shares of common stock of Exactus, Inc. (the "Issuer"), par value $0.0001 per share ("Shares"), that were distributed by Ceed2Med, LLC ("C2M") to one of its non-managing members in connection with its internal operational purposes. F2: This statement is jointly filed by and on behalf of each of C2M and Mr. Vladislav Yampolsky (the "Reporting Persons"). Mr. Yampolsky is the Managing Member of C2M. As such, Mr. Yampolsky may be deemed to beneficially own securities owned by C2M. F3: The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that such persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The reporting persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such persons in such securities. F4: Represents Shares directly beneficially owned by C2M. |
| Common Stock, Par Value $0.0001 per ShareSEC Table I · non-derivative | Direct | 1,000,000 |
Reported balance
Holding disclosure · report date 2019-12-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,000,000 F2: This statement is jointly filed by and on behalf of each of C2M and Mr. Vladislav Yampolsky (the "Reporting Persons"). Mr. Yampolsky is the Managing Member of C2M. As such, Mr. Yampolsky may be deemed to beneficially own securities owned by C2M. F3: The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that such persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The reporting persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such persons in such securities. F5: Represents certain restricted shares directly beneficially owned by Mr. Yampolsky, which vest equally over 48 months commencing October 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Exactus, Inc. (the "Issuer"), par value $0.0001 per share ("Shares"), that were distributed by Ceed2Med, LLC ("C2M") to one of its non-managing members in connection with its internal operational purposes.
F2: This statement is jointly filed by and on behalf of each of C2M and Mr. Vladislav Yampolsky (the "Reporting Persons"). Mr. Yampolsky is the Managing Member of C2M. As such, Mr. Yampolsky may be deemed to beneficially own securities owned by C2M.
F3: The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that such persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The reporting persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such persons in such securities.
F4: Represents Shares directly beneficially owned by C2M.
F5: Represents certain restricted shares directly beneficially owned by Mr. Yampolsky, which vest equally over 48 months commencing October 1, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 11, 2019 Filed Dec 13, 2019 22:39 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | OtherCommon Stock, Par Value $0.0001 per Share | 1,200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001504 · form4-12132019_021251.xml · nonDerivative · entry 1 Ceed2Med LLC · CIK 0001764452 · Director · 10% owner Yampolsky Vladislav · CIK 0001782054 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,435,691 F1 · shares: Represents shares of common stock of Exactus, Inc. (the "Issuer"), par value $0.0001 per share ("Shares"), that were distributed by Ceed2Med, LLC ("C2M") to one of its non-managing members in connection with its internal operational purposes. F2 · ownership.direct: This statement is jointly filed by and on behalf of each of C2M and Mr. Vladislav Yampolsky (the "Reporting Persons"). Mr. Yampolsky is the Managing Member of C2M. As such, Mr. Yampolsky may be deemed to beneficially own securities owned by C2M. F3 · ownership.direct: The Reporting Persons state that neither the filing of this statement nor anything herein shall be deemed an admission that such persons are, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise, the beneficial owners of any securities covered by this statement. The reporting persons disclaim beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such persons in such securities. F4 · ownership.direct: Represents Shares directly beneficially owned by C2M. Read SEC document |
| September 13, 2019 Filed Oct 4, 2019 19:03 UTC | PANACEA LIFE SCIENCES HOLDINGS, INC. EXDI · Entity 9699 | GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001153 · form4-10042019_121033.xml · nonDerivative · entry 1 Yampolsky Vladislav · CIK 0001782054 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 F1 · shares: Award of restricted common stock that vests equally over 48 months commencing October 1, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.